{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:59:12Z","timestamp":1785131952613,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100032683","name":"Akita University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032683","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Achieving treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) requires several years of tyrosine kinase inhibitor (TKI) therapy and a sustained deep molecular response (DMR). We report an exceptional case of a 54-year-old woman who achieved long-term TFR despite discontinuing dasatinib after only 9\u00a0months due to grade 3 interstitial pneumonitis. At the time of discontinuation, the duration of DMR was 128\u00a0days. Following cessation, BCR::ABL1 transcript levels transiently rebounded to 0.0729% on the International Scale but subsequently declined spontaneously without resumption of TKI therapy. The patient has remained in TFR for more than 7\u00a0years. Immunological analysis revealed clonal expansion of a unique CD56\n                    <jats:sup>+<\/jats:sup>\n                    CD57\n                    <jats:sup>+<\/jats:sup>\n                    CD8\n                    <jats:sup>dim<\/jats:sup>\n                    T-cell population possessing natural killer (NK)-like properties, as confirmed by T-cell receptor gene rearrangement analysis. This specific clone persisted after discontinuation, suggesting a role in the sustained immune surveillance of residual leukemia stem cells. These findings suggest that the quality of immune reconstitution, specifically the induction of innate-like effector T-cell clones, may be a more critical determinant of TFR success than the absolute duration of therapy.\n                  <\/jats:p>","DOI":"10.1007\/s12185-026-04241-y","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:46:37Z","timestamp":1782859597000},"page":"295-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis"],"prefix":"10.1007","volume":"124","author":[{"given":"Makoto","family":"Kashimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Mei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"4241_CR1","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.23.01647","volume":"42","author":"FX Mahon","year":"2024","unstructured":"Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al. European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: Final analysis and novel prognostic factors for treatment-free remission. J Clin Oncol. 2024;42:1875\u201380.","journal-title":"J Clin Oncol"},{"key":"4241_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-026-04184-4","author":"N Takahashi","year":"2026","unstructured":"Takahashi N, Kimura S, Matsuki E, Ono T, Doki N, Iino M, et al. Five-year interim analysis of J-SKI: An observational study of TKI discontinuation in patients with CML in Japan. Int J Hematol. 2026. https:\/\/doi.org\/10.1007\/s12185-026-04184-4.","journal-title":"Int J Hematol"},{"key":"4241_CR3","unstructured":"NCCN. NCCN clinical practice guidelines in oncology 2025. [version 1.2026:]"},{"key":"4241_CR4","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"4241_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12185-024-03865-2","volume":"121","author":"N Takahashi","year":"2023","unstructured":"Takahashi N, Takenaka K, Iriyama N, Kirito K, Kawaguchi T, Kimura S, et al. JSH practical guidelines for hematological malignancies, 2023: Leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2023;121:5\u201338.","journal-title":"Int J Hematol"},{"key":"4241_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-024-01025-7","volume":"14","author":"M Bonifacio","year":"2024","unstructured":"Bonifacio M, Scaffidi L, Miggiano MC, Facchinelli D, Tosoni L, Pezone S, et al. A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements. Blood Cancer J. 2024;14:53.","journal-title":"Blood Cancer J"},{"key":"4241_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"4241_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424\u201330.","journal-title":"J Clin Oncol"},{"key":"4241_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s12185-021-03117-7","volume":"113","author":"H Ureshino","year":"2021","unstructured":"Ureshino H. Treatment-free remission and immunity in chronic myeloid leukemia. Int J Hematol. 2021;113:642\u20137.","journal-title":"Int J Hematol"},{"key":"4241_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/bjh.17807","volume":"196","author":"DDH Kim","year":"2022","unstructured":"Kim DDH, Kim TS, Atenafu EG, Novitzky Basso I, Forrest D, Bence-Bruckler I, et al. BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. Br J Haematol. 2022;196:136\u201345.","journal-title":"Br J Haematol"},{"key":"4241_CR11","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood.2020005514","volume":"137","author":"N Shanmuganathan","year":"2021","unstructured":"Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137:1196\u2013207.","journal-title":"Blood"},{"key":"4241_CR12","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398\u2013405.","journal-title":"Leukemia"},{"key":"4241_CR13","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/leu.2011.135","volume":"25","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25:1587\u201397.","journal-title":"Leukemia"},{"key":"4241_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fimmu.2017.00316","volume":"8","author":"A Barbarin","year":"2017","unstructured":"Barbarin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lefevre L, et al. Phenotype of NK-like CD8(+) T Cells with innate features in humans and their relevance in cancer diseases. Front Immunol. 2017;8:316.","journal-title":"Front Immunol"},{"key":"4241_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00262-025-04256-0","volume":"75","author":"E Cayssials","year":"2025","unstructured":"Cayssials E, Lef\u00e8vre L, Decroos A, Jacomet F, Piccirilli N, Tartarin F, et al. Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients. Cancer Immunol Immunother. 2025;75:16.","journal-title":"Cancer Immunol Immunother"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04241-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04241-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04241-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:04:40Z","timestamp":1785128680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04241-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4241"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04241-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors state that they have no conflict of interest (COI) to declare regarding this case report.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study.","order":2,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}